Latest / GeriPal - A Geriatrics and Palliative Medicine Podcast
Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
We've talked at length on prior podcasts about the failures of aducnumab, Biogen, and the FDA's decision to approve it.
But wait, there's a shiny new anti-amyloid drug, lecanemab! (No it's not just the French version of Aducanumab).
In an article in the NEJM (a published article this time, wonder of wonders!) lecanemab was shown to slow the rate of cognitive decline by 0.45 points on an 18 point cognitive scale compared to placebo. Wow! Wow? Wait, what?
On today's podcast we talk with Jason Karlawish, who we've had on previously talking about his book The Problem of Alzheimer's and with Aaron…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.